Wysong, Ashley
Somani, Ally‐Khan
Ibrahim, Sherrif F.
Cañueto, Javier
Fitzgerald, Alison L.
Siegel, Jennifer J.
Prasai, Anesh
Goldberg, Matthew S.
Farberg, Aaron S.
Regula, Christie
Bar, Anna
Kasprzak, Julia
Brodland, David G.
Koyfman, Shlomo A.
Arron, Sarah T.
Article History
Received: 3 January 2024
Accepted: 6 February 2024
First Online: 1 March 2024
Declarations
:
: Ashley Wysong and Anna Bar receive research funding from CBI. Christie Regula, Ally-Khan Somani, and Sherrif Ibrahim are speakers and principal investigators for CBI. Aaron Farberg is consultant for CBI and has funding from Regeneron, Replimune, Enspectra Health, Gerson Lehrman Group. Alison Fitzgerald, Jennifer Siegel, Anesh Prasai, and Matthew Goldberg are employees, stock and options holders for CBI. Shlomo Koyfman is a consultant for CBI, Merck, BMS, Regeneron and Galera therapeutics; has research support from Merk, BMS and Regeron and honoraria from UpToDate and Varian. Sarah Arron is a paid consultant for Enspectra Health, CBI, and WorldCare Clinical; paid speaker bureaus for Regeneron and CBI; paid expert testimony from Forensis, Inc, and Muro & Lampe; travel expenses paid by CBI; paid participation on a data safety monitoring board for Replimune; paid advisory board participation for Regeneron, Dermatology Times/Multimedia Medical, and Matrix Medical; leadership in the International Transplant Skin Cancer Collaborative; stock holding in Rakuten Medical and Enspectra Health, with stock held by spouse in Genentech and 23andMe. All remaining authors participated as investigators for CBI during this study.
: The authors have obtained appropriate institutional review board (IRB) ethical approval via Western IRB (approval number 20162697), and a waiver of consent was obtained. The study adhered to the Declaration of Helsinki and its subsequent amendments.